MedTrace Logo

Pulmozyme for Sjogren's Associated Cough

NCT01357447 · Status: WITHDRAWN · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2020-01-18

No results posted yet for this study

Summary

Patients with Sjogren's disease have destruction of the mucus secreting cells in the airway. This manifestation of the disease leads to the common complaint of persistent dry cough that is seen in many of these patients. This study is aimed at determining whether the regular use of Pulmozyme will result in decreased cough and improved quality of life.

Conditions

  • Sjogren's Syndrome
  • Cough

Interventions

DRUG

Dornase alfa

Dose: 2.5 mg solution BID via nebuliser for 2 weeks

DRUG

Saline

2.5 ml via nebuliser BID for 2 weeks (alternating with study drug)

Sponsors & Collaborators

  • UConn Health

    lead OTHER

Principal Investigators

  • Metersky L Mark, MD · University of CT Health Center

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-05-31
Primary Completion
2012-03-31
Completion
2012-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01357447 on ClinicalTrials.gov